Leading Medical Device CRO Symbios Clinical Acquired by Medpace
- Fairmount Partners
- Apr 6, 2010
- 2 min read
CINCINNATI, OH — April 6, 2010 — Medpace, a global, full-service clinical research organization (CRO) has acquired Symbios Clinical, one of the largest CROs dedicated to medical device clinical trials. Symbios supports the full spectrum of medical device trials including pre-market, post-approval and post-market / outcomes trials.
This acquisition allows the integration of Medpace’s therapeutic expertise and global reach with the device expertise of Symbios to offer best-in-class clinical trial management solutions to medical device companies. Medpace currently offers full service strategic consultation, Phase I-IV clinical trial management, bio-imaging, central laboratory, clinical pharmacology, and bioanalytical support for pharmaceutical and biotechnology companies, which Symbios will be now able to leverage to compliment their service offering for medical device companies as well.
Symbios was founded and currently led by Chief Executive Officer Ryan Wilson, BS, MBA, and Managing Partner, Ethan Rooney, BS, MBA. The Symbios management team brings extensive experience in medical device research. Ryan Wilson, along with his current management team, will continue to lead Symbios Clinical, as a member of the Medpace group of companies. They serve the medical device industry from their headquarters outside of Minneapolis, Minnesota.
“I am pleased to welcome Ryan Wilson and the Symbios team to Medpace as the head our medical device business” said Dr. August Troendle, President and CEO, Medpace. “Ryan and his team have built a successful company in the growing area of medical device research. They hold a unique position as a CRO dedicated to conducting medical device trials. The ability of Medpace to tap into this innovative company for benefit of our existing and new Sponsors will be valuable as yet another service area for Medpace, and allow Symbios to benefit from our established global infrastructure.”
Fairmount Partners advised Symbios and originated and structured the transaction.
About Medpace
Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry’s most experienced and therapeutically focused teams to execute at every level of the company’s operations, providing complete and seamless drug development services. In June 2009 Medpace was rated as the best CRO by U.S. investigators in the 2009 CenterWatch Site Survey.
Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development – from program planning and execution to product approval.
With 900+ employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, and central image management and reading from Imagepace. www.medpace.com
Principals of Fairmount Partners acted as advisors to Symbios Clinical in this transaction.
Contact
Neal McCarthy
Managing Director, Fairmount Partners